Alnylam Pharmaceuticals
ALNY
Alnylam Pharmaceuticals (ALNY) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| BMO Capital | Initiated Coverage | Outperform | $318.00 | Aug 19, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $256.00 from $316.00 | Aug 14, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $455.00 from $485.00 | Aug 4, 2026 |
| Truist Securities | Maintained | Buy | $315.00 from $410.00 | Aug 4, 2026 |
| Barclays | Maintained | Overweight | $450.00 from $527.00 | Aug 3, 2026 |
| Citigroup | Maintained | Buy | $340.00 from $380.00 | Aug 3, 2026 |
| Raymond James | Upgraded | Outperform → Strong Buy | $420.00 | Aug 3, 2026 |
| Chardan Capital | Maintained | Buy | $425.00 | Jul 31, 2026 |
| Stifel | Maintained | Buy | $318.00 from $444.00 | Jul 31, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $316.00 from $377.00 | Jul 31, 2026 |
| Oppenheimer | Maintained | Outperform | $350.00 from $500.00 | Jul 31, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $300.00 from $400.00 | Jul 31, 2026 |
| RBC Capital | Maintained | Outperform | $350.00 from $445.00 | Jul 31, 2026 |
| JP Morgan | Maintained | Overweight | $375.00 from $400.00 | Jul 31, 2026 |
| Needham | Maintained | Buy | $357.00 from $510.00 | Jul 30, 2026 |
| JP Morgan | Maintained | Overweight | $400.00 from $420.00 | Jul 22, 2026 |
| B of A Securities | Maintained | Buy | $410.00 from $460.00 | Jul 14, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $485.00 from $470.00 | Jul 13, 2026 |
| Truist Securities | Maintained | Buy | $410.00 from $505.00 | Jul 13, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $400.00 from $370.00 | Jul 10, 2026 |
Frequently asked questions
What is the latest analyst rating on ALNY?
On Aug 19, 2026, BMO Capital initiated coverage of Alnylam Pharmaceuticals at Outperform with a price target of $318.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.